To further understand the mechanism of TRAIL resistance in the CD133+ CSCs, functional assays incorporating MSC-TRAIL and a knockdown or sensitized model of the CSCs and NSCLC cell lines can be performed in the future. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.